How long does Pralsetinib usually last?

Pralsetinib is a highly selective RETkinase inhibitor, mainly used to treat patients with non-small cell lung cancer (NSCLC) and thyroid cancer with RET gene fusion. As a precision targeted therapy drug, platinib inhibits the growth and spread of tumor cells from the source by blocking the RET fusion protein signaling pathway. In clinical practice, the drug has shown significant efficacy, especially for patients who have previously received multiple lines of treatment but failed to respond. Pratinib provides a new treatment option.

The duration of drug effect maintenance generally depends on the patient's individual condition, RET mutation type, tumor burden, drug sensitivity and whether the drug is taken on time and other factors. International clinical studies such as the ARROW study have shown that platinib is effective in RETfusion-positive NSCLC span>Among the patients, the objective response rate (ORR) reaches more than 60%, and the remission of some patients can last for more than a year, or even longer. Durable remission effects have also been observed for thyroid cancer patients with RET mutations, with some patients having disease control times of more than 18 months.

However, there are certain individual differences in the maintenance time of platinib's efficacy. In some patients, tumors may gradually develop resistance mechanisms over time, such as the RET gene mutating again or activating other evasion signaling pathways, which will affect the sustained effect of the drug. In such cases, patients may need to adjust their treatment plan, such as combining it with other targeted drugs, immunotherapy, or changing treatment strategies. Therefore, imaging evaluations and genetic testing should be performed regularly during medication to monitor efficacy and potential risk of drug resistance.

In general, platinib, as a first-line or late-line treatment for RETfusion-positive tumors, can bring sustained efficacy from several months to more than a year in most patients. However, patients need to take medications on time, monitor changes in condition, and communicate closely with doctors in order to adjust treatment strategies in a timely manner to maximize and sustain drug effects.

Reference materials:https://gavreto.com/